
On 19 June, Nigeria joined the global community in commemorating World Sickle Cell Day, shining a spotlight on one of the country’s most pressing yet long-neglected health challenges. With the theme “Transforming Care and Strengthening Communities,” the event aimed not only to raise awareness but also to rally meaningful support for the millions of Nigerians living with sickle cell disorder (SCD)—a severe inherited blood condition that claims the lives of roughly 150,000 Nigerian infants annually and continues to affect millions more.
Globally, more than 100 million people live with SCD. However, Nigeria remains the epicentre of the disease burden, accounting for the highest prevalence worldwide. One in four Nigerians carries the sickle cell gene, and approximately 150,000 infants die from the disorder each year—representing around 8 percent of total infant mortality. Beyond these harrowing figures, survivors must contend with a lifetime of health complications—such as stroke, organ damage, recurrent infections, and debilitating pain crises—often compounded by social stigma, disrupted education, diminished employment opportunities, and mental health stress. For their families and caregivers, the burden is no less overwhelming.
This year, the Federal Government, through the Ministry of Health and Social Welfare, introduced a new nine-point agenda aimed at reducing the country’s SCD burden through expanded prevention, care delivery, and community empowerment. The agenda outlines intentions to train primary healthcare workers in universal newborn screening, beginning in the South-West; to establish six regional centres of excellence equipped with advanced diagnostic capabilities; to harmonise screening through a national desk guide and standard operating procedures; and to update existing SCD guidelines in line with WHO standards.
It also includes plans to integrate SCD services into the wider non-communicable disease (NCD) framework at the primary care level, adapt the WHO’s essential intervention package into a Nigerian-specific model, form a national technical committee to guide multisectoral implementation, and launch nationwide advocacy campaigns to promote genotype testing, genetic counselling, and access to treatment. Finally, the government intends to pilot PEN-Plus strategies for SCD, Type 1 diabetes, and rheumatic heart disease, in partnership with the World Health Organisation and the Clinton Health Access Initiative.
There is no doubt that the agenda is ambitious and, on paper, promising. However, Nigerians have long grown weary of well-crafted policies that do not translate into measurable progress. Despite decades of declarations and modest initiatives, the country has yet to record any significant improvement in SCD-related outcomes. Civil society stakeholders continue to express frustration. Mr Caleb Audu, programme director of the Sickle Cell Foundation Nigeria, recently lamented the lack of strategic, coordinated, and inclusive interventions. His words echo the disillusionment of families who have received little support while navigating the painful realities of SCD with limited information, inadequate infrastructure, and rising treatment costs.
To ensure this new roadmap does not become another well-meaning but unfulfilled promise, Nigeria must be willing to confront the deeper systemic issues that have consistently hampered progress. For instance, the plan to train primary healthcare workers in newborn screening is commendable, but it remains confined to the South-West region. If not scaled rapidly and equitably, it risks reinforcing existing disparities in access to care. Given that SCD affects every part of the country, universal access to early diagnosis must be a non-negotiable national priority.
Moreover, training healthcare personnel without upgrading the infrastructure in which they work is a hollow gesture. Of Nigeria’s 30,000 primary healthcare centres, nearly 80 percent are ill-equipped, under-staffed, or functionally inactive due to poor facilities, lack of electricity, or inaccessible locations. Without substantial investment in infrastructure, even the most skilled personnel will remain hamstrung, and the gains anticipated from the training programme will be significantly undermined.
History has shown that ambitious policies alone do not produce results. What determines impact is consistent follow-through, adequate funding, robust coordination, and strong political will. Past national health strategies have often failed because implementation lacked transparency, timelines, and accountability. If this government is serious about reversing the sickle cell crisis, then mechanisms for continuous monitoring, independent evaluation, and public reporting must be embedded into the process from the outset.
Additionally, tackling SCD in Nigeria will require more than government action. The success of any national initiative will hinge on the strength of partnerships with NGOs, medical professionals, pharmaceutical companies, community leaders, and patients themselves. Public-private partnerships, investment in local drug production, and sustained advocacy are urgently needed to improve access to affordable treatments, particularly disease-modifying drugs like hydroxyurea, which remain out of reach for many families.
The Federal Government’s nine-point agenda is a step in the right direction, but it is only a beginning. Transforming care for SCD patients in Nigeria demands more than policy documents and pledges. It calls for tangible, measurable actions that prioritise the lives of vulnerable citizens and build resilient systems of care. Let this be the administration that breaks the cycle of neglect—not just by launching an agenda, but by sustaining the political will, investment, and coordination required to carry it through to success.





